백신은 질병에 대한 장기적이고 지속적인 면역력을 제공합니다. 백신은 70년 이상 예방 의학의 기초가 되어 왔으며, 특정 질병에 대한 면역 반응을 자극합니다. 효과적인 백신이 널리 보급되면서 많은 치명적인 질병이 거의 근절되었고, 백신 접종은 20세기 공중보건의 가장 큰 성과 중 하나가 되었습니다.
공공 예방접종 프로그램 덕분에 백신으로 예방할 수 있는 질병과 관련 사망은 선진국에서 드물어지고 전 세계적으로 감소하고 있습니다. 천연두는 근절되었고, 소아마비는 북미와 남미에서 퇴치되었으며, 홍역, 풍진, 파상풍, 디프테리아, 인플루엔자 B형 등의 질병은 억제되었습니다. 백신은 질병과 사망을 예방할 뿐만 아니라 삶의 질과 생산성을 향상시킵니다. 질병 발생을 예방하고 의료 비용을 절감하여 사회적으로 큰 이익을 가져왔습니다.
이 보고서는 세계 백신 시장을 조사했으며, 성인 및 소아 예방 백신에 대한 최신의 종합적인 분석을 제공합니다. 백신 카테고리별 시장 예측, 기업 점유율 데이터, 전문가 시장 예측, 다양한 질병 예방에 사용되는 인체용 백신 시장 동향도 조사했습니다. 특히 백신으로 예방할 수 있는 질병에 대해 이미 상용화된 백신과 개발 중인 백신 모두에 초점을 맞추었습니다.
목차
제1장 주요 요약
제2장 백신 서론
서론
간략한 역사 : 백신 개발
인체 면역 체계
백신 작용기전
백신 유형
약독화(약화) 생바이러스
사멸한(비활성화) 바이러스
톡소이드 백신
유전자 재조합/변형 백신
아단위 백신
결합 백신
DNA 백신
메신저 RNA 백신
재조합 벡터 백신
백신 분류
백신 승인 프로세스
FDA EUA 승인
세계보건기구 사전 적격성 평가 백신
팬데믹
HIN1 2009/2010년 팬데믹
코로나바이러스 팬데믹
에볼라 출혈열의 유행
제조 인센티브
합성 백신
인공지능 개발
제3장 소아 예방 백신
서론
미국의 아동 예방 접종
아동 예방 접종률
백신 전달 시스템의 과제
권장 아동 예방 접종 일정
주별 예방 접종 추천 사항
COVID-19 예방 접종 일정
유엔의 이니셔티브
소아 백신 시장
경쟁 개요
제4장 성인 예방 백신
서론
권장 성인 예방 접종
세계의 인플루엔자 감시 프로그램
미국의 감시
WHO의 국제 보건 규칙
성인 예방 백신 시장
시장 : 시장 전체 성인용 비코비드 백신 매출의 26% 창출
인플루엔자
경쟁 개요
제5장 백신 시장 전체
백신 시장 성장을 촉진하는 동향
시장 규모와 예측
소아용 백신
성인용 백신
COVID-19 시장 규모 추정 및 예측
지역별 백신 판매량
세계 기타 지역
미국
유럽
백신 시장의 경쟁사
백신 업계 뉴스
개발 중인 백신
COVID-19 백신 개발
제6장 기업 개요
AstraZeneca
Bavarian Nordic, A/S
Bharat Biotech International Ltd.
Bio Farma
BioNTech SE
CSL Limited/Seqirus
Dynavax Technologies
Emergent BioSolutions, Inc.
GlaxoSmithKline, Inc.
Inovio Pharmaceuticals, Inc.
Johnson & Johnson/Crucell/Janssen
Merck & Co, Inc.
Moderna, Inc.
Novavax, Inc.
Pfizer, Inc.
Sanofi Pasteur
Serum Institute, Inc.
Sinovac Biotech Ltd.
Soligenix, Inc.
Takeda Pharmaceutical Co, Ltd.
Valneva SE
LSH
영문 목차
영문목차
Vaccines offer long-term or permanent immunity against diseases. They have been a cornerstone of preventive medicine for over 70 years, stimulating an immune response to specific diseases. The widespread adoption of effective vaccines has led to the near-elimination of many deadly diseases, making vaccination one of the greatest public health achievements of the 20th century.
Thanks to public vaccination programs, vaccine-preventable diseases and related deaths are now rare in developed nations and decreasing globally. Smallpox has been eradicated, polio eliminated in the Americas, and diseases like measles, rubella, tetanus, diphtheria, and Haemophilus influenzae type b controlled. Beyond preventing illness and death, vaccines also improve quality of life and productivity. They help prevent disease outbreaks and reduce healthcare costs, providing significant societal benefits.
Kalorama Information's latest report, "The World Market for Vaccines, 2024", offers the most up-to-date and comprehensive analysis of adult and pediatric preventative vaccines. Since the early 2000s, Kalorama has consistently published new editions of The World Market for Vaccines every two years. The report includes market forecasts, company market share data, and expert market estimates for different vaccine categories.
"The World Market for Vaccines, 2024" also examines market trends for human vaccines used to prevent various diseases. It specifically focuses on both commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable. Additionally, the report discusses selected emerging vaccines in development.
Vaccines covered in the report with sizing and market share include:
The report also examines key companies involved in the market. Companies profiled in the report include:
AstraZeneca
Bavarian Nordic, A/S
Bharat Biotech International Ltd.
Bio Farma
BioNTech SE
CSL Limited/Seqirus
Dynavax Technologies
Emergent BioSolutions, Inc.
GlaxoSmithKline, Inc.
Inovio Pharmaceuticals, Inc.
Johnson & Johnson/Crucell/Janssen
Merck & Co, Inc.
Moderna, Inc
Novavax, Inc.
Pfizer, Inc.
Sanofi Pasteur
Serum Institute, Inc.
Sinovac Biotech Ltd.
Soligenix, Inc.
Takeda Pharmaceutical Co, Ltd.
Valneva SE
Scope and Methodology
"The World Market for Vaccines, 2024" examines the market for human vaccines used to prevent various types of disease. It focuses on commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable, with a discussion of selected emerging vaccines. It also covers the COVID-19 vaccine market landscape and estimated market opportunity during the forecast period. This report does not include therapeutic vaccines such as allergy and cancer vaccines.
Sales estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are provided for the 2023 year and forecasts are provided for 2028. Information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts' reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants' point of view and assess trends and form the basis of the forecasting and competitive analysis.
It should also be noted that due to the very broad scope of this report, with the exception of healthcare spending forecasts, data provided is representative but is not intended to be exhaustive. This includes, for example, tables of vaccines in development and regional economic indicators, etc. Additionally, some statistics, such as those related to venture capital investment, are subject to wide divergences across different sources; where data could not be confidently obtained, trends were discussed rather than absolute numerical values.
Figure 1-2: Regional Non-COVID vs COVID Vaccine Markets, 2018-2028 ($)
Competitive Analysis
Chapter 2: Introduction to Vaccines
Introduction
Table 2-1: Global Reported Cases of Vaccine Preventable Diseases, 2000 vs. 2022
Figure 2-1: CDC Infographic: Global Impact of Vaccines in Reducing Vaccine-Preventable Disease Morbidity and Mortality
A Brief History: The Development of Vaccines
The Human Immune System
Vaccine Mechanism of Action
Types of Vaccines
Attenuated (Weakened) Live Viruses
Figure 2-2: Attenuated Virus Production
Killed (Inactivated) Viruses
Toxoid Vaccines
Genetically Engineered/Modified Vaccines
Subunit Vaccines
Conjugate Vaccines
DNA Vaccines
Messenger RNA Vaccines
Recombinant Vector Vaccines
Classification of Vaccines
Vaccine Approval Process
Figure 2-3: Global Vaccine Sales by Region, 2023
FDA EUA Approval
World Health Organization Prequalified Vaccines
Table 2-3: WHO Prequalified BCG Vaccines
Table 2-4: WHO Prequalified Cholera Vaccines
Table 2-5: WHO Prequalified Diphtheria-Tetanus Vaccines
Table 2-6: WHO Prequalified Diphtheria-Tetanus-Pertussis Vaccines
Table 2-7: WHO Prequalified Diphtheria-Tetanus-Pertussis-Hemophilus influenzae type b Vaccines
Table 2-8: WHO Prequalified Diphtheria-Tetanus-Pertussis and Hepatitis B Vaccines
Table 2-9: WHO Prequalified Diphtheria-Tetanus-Pertussis-Hepatitis B-Hemophilus influenzae type b Vaccines
Table 2-10: WHO Prequalified Hemophilus influenzae type b Vaccines
Table 2-11: WHO Prequalified Hepatitis A Vaccines
Table 2-12: WHO Prequalified Hepatitis B Vaccines
Table 2-13: WHO Prequalified Human Papillomavirus Vaccines
Table 2-14: WHO Prequalified Influenza Vaccines
Table 2-15: WHO Prequalified Japanese Encephalitis Vaccines
Table 2-16: WHO Prequalified Measles Vaccines
Table 2-17: WHO Prequalified Measles and Rubella Vaccines
Table 2-18: WHO Prequalified Measles, Mumps and Rubella Vaccines
Table 2-19: WHO Prequalified Meningococcal A Vaccines
Table 2-20: WHO Prequalified Pneumococcal Vaccines
Table 2-21: WHO Prequalified Polio Vaccines
Table 2-22: WHO Prequalified Rabies Vaccines
Table 2-23: WHO Prequalified Rotavirus Vaccines
Table 2-24: WHO Prequalified Rubella Vaccines
Table 2-25: WHO Prequalified Tetanus Toxoid Vaccines
Table 2-26: WHO Prequalified Typhoid Vaccines
Table 2-27: WHO Prequalified Varicella Vaccine
Table 2-28: WHO Prequalified Yellow Fever Vaccines
Table 2-29: WHO Prequalified Other Vaccines
Pandemics
HIN1 Pandemic of 2009/2010
Coronavirus Pandemic
Figure 2-4: Leading COVID-19 Vaccines: Supplied Dose Estimates
Ebola Epidemics
Manufacturing Incentives
Synthetic Vaccines
Artificial Intelligence Development
Chapter 3: Pediatric Preventative Vaccines
Introduction
Table 3-1: Immunization Rates for Vaccines Recommended by the WHO, 2022
Childhood Immunization in the United States
Childhood Immunization Rates
Challenges to the Vaccine Delivery System
Recommended Childhood Immunization Schedule
Figure 3-1: CDC Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024
Figure 3-2: CDC Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2024
State Immunization Recommendations
Figure 3-3: Exemptions Permitted for State Childcare and School (Grades PreK-12) Immunization Requirements, United States, March 2023
COVID-19 Vaccination Schedule
United Nations Initiatives
Pediatric Vaccine Markets
Table 3-2: Global Market for Pediatric Preventive Vaccines, by Type (Hepatitis, Pediatric Routine [HiB, MMR, Combinations, Polio, Varicella], Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others), 2023-2028 ($M)
Figure 3-4: Global Market for Pediatric Preventive Vaccines, by Type (Hepatitis, Pediatric Routine [HiB, MMR, Combinations, Polio, Varicella], Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others), 2023-2028 (%)
Figure 3-5: Market Share of Pediatric Preventive Vaccines, by Type (Hepatitis, Pediatric Routine [HiB, MMR, Combinations, Polio, Varicella], Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others), 2023 (%)
Competitive Summary
Table 3-3: Major Manufacturers' Shares of the Global Pediatric Preventative Vaccine Market, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Merck, Moderna, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023 (%, $M)
Figure 3-6: Global Pediatric Preventative Vaccines Market Share, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Merck, Moderna, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023, (%)
Chapter 4: Adult Preventative Vaccines
Introduction
Recommended Adult Immunizations
Figure 4-1: CDC Recommended Immunization Schedule: Adults, 19 years and over
Global Influenza Surveillance Program
U.S. Surveillance
Table: 4-1: U.S. Influenza Vaccine Effectiveness, 2004-2023 (%)
Figure 4-2: U.S. Influenza Vaccine Effectiveness, by Season, 2009-2023, (%)
WHO International Health Regulations
Adult Preventive Vaccine Markets
Table 4-2: Global Market for Adult Preventive Vaccines, by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other) 2023-2028 ($M)
Figure 4-3: Global Market for Adult Preventive Vaccines, by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other), 2023-2028 (%)
Figure 4-4: Market Share of Adult Preventive Vaccines, by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other) 2023 (%)
Market: Generating 26% of Total Adult Non-COVID Vaccine Sales
Figure 4-5: U.S. Seasonal Influenza Vaccination, by Age Group and Season, 2010-2023 (%)
Figure 4-6: U.S. Seasonal Influenza Vaccination Coverage and HP 2020 Target - Total Population - Seasons, 2010-2023 (%)
Influenza
Figure 4-7: Estimated U.S. Flu Burden, by Season 2010-2023
Table 4-3: Estimated Number of Influenza Illnesses Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
Table 4-4: Estimated Number of Influenza Medical Visits Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
Table 4-5: Estimated Number and Fraction of Influenza Hospitalizations Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
Table 4-6: Estimated Number of Influenza Deaths Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
Figure 4-8: Estimated U.S. Flu Burden Prevented by Vaccination (Deaths, Hospitalizations, Medical Visits, Symptomatic Illness), 2010-2023
Table 4-7: WHO Pandemic Classification Schedule
Competitive Summary
Table 4-8: Major Manufacturers' Shares of the Global Adult Preventative Vaccine Market, by Company (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023 (%, $M)
Figure 4-9: Global Adult Preventative Vaccines Market Share, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023 (%)
Chapter 5: Total Vaccines Market
Trends Driving the Vaccines Market
Figure 5-1: Sales Growth of Vaccines vs. Pharmaceuticals, 2015-2025
Market Size and Forecast
Table 5-1: Total Global Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, RSV, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
Figure 5-2: Total World Market for Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, RSV, Shingles, Others [travel, endemic, etc.]),, 2023-2028 (Pediatric, Adult) (SM)
Figure 5-3: Total World Vaccine Market, Non-COVID and COVID Vaccine, 2023-2028 ($M)
Pediatric Vaccines
Adult Vaccines
Figure 5-4: Global Preventive Vaccine Market, by Broad Segment (Pediatric, Adult), Trend 2018-2028 ($M)
COVID-19 Market Size Estimates and Forecast
Table 5-2: Global COVID-19 Vaccine Market Cumulative Value, 2020-2023 ($M)
Figure 5-5: Global COVID-19 Vaccine by Unit Volume, Cumulative 2020-2023, Estimated Distribution by Country (Australia, Brazil, Canada, China, European Union, India, Japan, Russia, South Africa, South Korea, United States, Other Countries)
Vaccine Sales by Region
Rest of World
Table 5-3: Total ROW Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
United States
Table 5-4: Total U.S. Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, RSV, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
Europe
Table 5-5: Total Europe Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
Vaccine Market Competitors
Table 5-6: Major Manufacturers' Shares of the Global Vaccine Market, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, J&J/Janssen, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinova, Other), 2023 (%, $M)
Figure 5-6: Global Vaccines Market Share, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, J&J/Janssen, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinova, Other), 2023 (%)
Vaccine Industry News
Vaccines in Development
COVID-19 Vaccine Development
Figure 5-7: Regional Distribution of COVID-19 Vaccine Development, by Country and Region (Australia, Brazil, Canada, China, France, Indonesia, Japan, Mexico, Middle East, Philippines, Rest of Africa, Rest of Pacific, Rest of Europe, Rest of Latin America, South Africa, South Korea, United Kingdom, United States)
